This panel of real-world evidence (RWE) experts explore the economic impact and role of RWE in improving representativeness of research.
Despite the FDA guidance put forth in 2020 to enhance diversity in clinical trials, many populations remain underrepresented; particularly, racial and ethnic minority groups, women, and elderly individuals. This underrepresentation of disproportionately burdened groups limits information on therapeutic response, safety, and efficacy to a small subset of the population that tends to be healthier, more well-educated, and financially advantaged. Less than 20% of FDA drug approvals in the past 5 years had reported adverse effects or treatment benefits on Black participants1.
Approvals based on limited data can have detrimental economic as well as clinical consequences. In a 2022 report from the National Academies of Science Engineering and Medicine, it is estimated that hundreds of billions of dollars will be lost in the US over the next 25 years due to the impacts of underrepresentation in clinical trials, specifically in chronic diseases such as diabetes, heart disease, and hypertension2.
1) https://www.healthaffairs.org/doi/10.1377/hlthaff.2021.014322) https://healthpolicy.usc.edu/article/lack-of-diversity-in-clinical-trials-costs-billions-of-dollars-incentives-can-spur-innovation/
Presenters
Bruce A. Feinberg
Bruce Feinberg, D.O., is Vice President, Clinical Affairs and Chief Medical Officer for Cardinal Health Specialty Solutions. He is nationally recognized for his expertise in specialty oncology and the business of specialty healthcare.
Danielle Gentile
Danielle Gentile, PhD is a Scientist for Real-World Evidence and Insights at Cardinal Health. She investigates the health outcomes of patients treated in real-world settings outside of clinical trials. She earned her PhD in Health Promotion, Education, and Behavior from the Arnold School of Public Health at the University of South Carolina.
Parisa Asgarisabet
Parisa Asgarisabet, PhD is the Lead statistician for Real-World Evidence and Insights team at Cardinal Health. Her expertise lies in statistical analysis, database management, and clinical and economic outcomes research of real-world data from chart review forms, administrative claim databases, disease registries, and patient-reported data.
Alexandrina Balanean
Alexandrina Balanean is the Lead Publications Scientist, Strategic Research, at Cardinal Health, working in the greater Chicago area. She has over 15 years of experience in scientific research and communication, including medical writing, editing, and managing peer-reviewed journals.
Sponsor
Cardinal Health
Content Partners
HealthEconomics.com
HealthEconomics.com is the world’s largest Connected Community™ for Value, Evidence and Access in the life sciences industry.
HealthEconomics.com provides a single global link to the health economic and outcomes research (HEOR), real-world evidence (RWE), and Market Access (MA) stakeholder communities. Since 1993, we have provided unparalleled access to drive business, improve knowledge, and connect researchers and payer decision-makers world-wide.
Our 27,000 engaged readers rely on HealthEconomics.com as the most reliable, credible and curated digital hub for the latest news, insights, educational opportunities, and industry benchmarks in HEOR, RWE and MA. Our advertisers, numbering more than 500 with a 91% retention rate, depend upon HealthEconomics.com for best-in-class global brand awareness and business development solutions. Our aim is to connect people with expert-driven content and resources — all in one place — with the corporate mission to advance communication about healthcare value.
